Drug Warning: Rezulin

Generic name: troglitazone

Purpose: Was used to treat patients suffering from type 2 diabetes, also referred to as adult onset diabetes, prior to its being withdrawn from the market in March of 2000 at the request of the FDA.

Side Effects Reported

• Liver problems that resulted in death or the need for a liver transplant.

Industry Report

In March of 2000, the FDA requested that Rezulin be voluntarily withdrawn from the market, due to Rezulin's link to severe liver problems. Some reports have linked Rezulin to 90 cases of liver failure. Of those 90 cases of liver failure, 63 resulted in death, while some others had to receive liver transplants. As links to liver problems increased over the years since the drug was introduced in 1997, Rezulin's labeling had been changed to indicate the risk of liver problems and to encourage patients to carefully watch for liver disease.

Check out more drug injury information on Rezulin:

• Pfizer Rezulin Liability

Seeger Weiss is not currently pursuing lawsuits on this drug, but its drug warnings will remain on our radar.

• Seeger Weiss Wins 5th Verdict Against Accutane Maker, Dealing a $25.16 Million Blow
• Seeger Weiss Delivers $11 Million Verdict to Small, Family Farms Overrun by Corporate Agriculture's Waste
• Seeger Weiss Obtains $41.5 Million Global Resolution of Zetia and Vytorin Claims
• Seeger Weiss Secures $4.85 Billion Vioxx Settlement from Merck
• Seeger Weiss Named to National Law Journal's Plaintiffs' Hot List Three Years Running
• Seeger Weiss & Milberg Drive Bernie Madoff into Personal Bankruptcy